Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST).
about
Biomarkers in cancer staging, prognosis and treatment selectionAntibody-based protein multiplex platforms: technical and operational challenges.Biomarker Validation for Aging: Lessons from mtDNA Heteroplasmy Analyses in Early Cancer Detection.Standards for immunohistochemical imaging: a protein reference device for biomarker quantitation.Novel diagnostic biomarkers for prostate cancer.Reliability of tumor markers, chemokines, and metastasis-related molecules in serum.MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons.Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.Mitochondrial DNA as a cancer biomarkerAnalytical validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells.Development and use of biomarkers in oncology drug development.DNA methylation biomarkers of cancer: moving toward clinical application.Total protein is an effective loading control for cerebrospinal fluid western blotsAromatic amines and biomarkers of human exposure.Real-time telomerase activity measurements for detection of cancer.Biomarker method validation in anticancer drug developmentCytokines as biomarkers in rheumatoid arthritis.Variability in Platelet-Derived Growth Factor Receptor Alpha Antibody Specificity May Impact Clinical Utility of Immunohistochemistry Assays.
P2860
Q28278305-7770195F-7937-4B8C-8981-1F6E36E6CC7CQ28396909-4F63ECD6-FAC1-44EB-9AFC-D54CA01A4C52Q33520448-9488789A-FEC6-4652-97A4-955576F8E5B4Q34216960-4C2F0F7B-7270-4C01-981E-372EA22DA0A1Q34231678-720E8A16-8E15-4365-8C84-4F091CEBE631Q34402670-0D92F202-84DE-4A20-9FAC-EF5F8F8785B4Q34685896-CB8FC09F-CC3D-4B14-AB43-01861A237E33Q34940834-D309CD74-D2F5-4214-9503-126A20FBBB4EQ35789945-DAC5E85A-3428-4CEF-B852-4E437F6E410EQ35790317-86DB4CB1-9442-4C28-9804-582B7CB113B8Q35812532-D84DE31B-8CB3-4935-88B3-ED019D26E266Q35873699-7E6BA0D6-2626-421D-8961-E2D7BDD9F747Q35966833-9CFA1D00-9D99-4DF2-9D8E-6DF850D6A73FQ36104064-5ECAB5F7-70B3-466E-B9AD-1B659BA729D2Q36252196-236FCB40-9112-4CB3-91FA-947D738EFFEAQ36484621-7429F8C1-67BF-4570-98D4-4AD62C260EB4Q37661549-8131D5A4-2DAB-49F4-ACFA-DD9B3CF1BC61Q38731617-205BEF3E-56E4-4655-8420-7A5D32476E91
P2860
Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST).
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Cancer biomarker validation: s ...... andards and Technology (NIST).
@ast
Cancer biomarker validation: s ...... andards and Technology (NIST).
@en
type
label
Cancer biomarker validation: s ...... andards and Technology (NIST).
@ast
Cancer biomarker validation: s ...... andards and Technology (NIST).
@en
prefLabel
Cancer biomarker validation: s ...... andards and Technology (NIST).
@ast
Cancer biomarker validation: s ...... andards and Technology (NIST).
@en
P1476
Cancer biomarker validation: s ...... andards and Technology (NIST).
@en
P2093
Peter E Barker
P304
P356
10.1111/J.1749-6632.2003.TB05969.X
P407
P577
2003-03-01T00:00:00Z